New pain pill AFA-281 takes first step in human safety trial
NCT ID NCT05547503
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and tolerability of a new drug called AFA-281 in 64 healthy volunteers. Participants received either a single dose or multiple doses over 14-21 days. The goal was to check for side effects and measure how the drug behaves in the body, not to treat pain. Results will help decide if further studies in people with pain are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AFA-281
What this could lead to
If successful, this could pave the way for further studies testing AFA-281 as a potential treatment for nerve or inflammatory pain.
What could go wrong
This is a very early Phase 1 trial in healthy volunteers, not patients. It only checks safety and how the drug moves through the body, not whether it works for pain. Many early-stage drugs fail in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN, NEUROPATHIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExcel CNS
Los Alamitos, California, 90720, United States